This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2012 Financial Results

Stocks in this article: RPRX

Total revenues and other income increased to $3,000 for the year ended December 31, 2012 as compared to $2,000 for the same period in the prior year. This increase is primarily due to an increase in interest income due to higher cash balances.

As of December 31, 2012, the Company had 17,160,155 shares of common stock outstanding. On January 29, 2013, 872,133 Series A Warrants and 713,741 Series B Warrants were exercised using the cashless exercise provision of the Warrant Agreements, resulting in the issuance of 1,483,831 shares of our common stock. As a result of this exercise, we currently have 18,643,986 shares of common stock outstanding.

About Repros Therapeutics Inc. ®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including the ability to raise additional needed capital on a timely basis in order for it to continue to fund development of its Androxal® and Proellex® programs and have success in the clinical development of its technologies, the reliability of interim results to predict final study outcomes, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at .

The Repros Therapeutics Inc. logo is available at

(in thousands except per share amounts)
  Three Months Ended Twelve Months Ended
  December 31, December 31,
  2012 2011 2012 2011
Interest income  $ 2  $ 1  $ 3  $ 2
Total revenues  2  1  3  2
Research and development  6,568  1,701  13,343  8,682
General and administrative  1,479  1,032  4,827  3,811
Total expenses  8,047  2,733  18,170  12,493
Net loss  $ (8,045)  $ (2,732)  $ (18,167)  $ (12,491)
Net loss per share - basic and diluted  $ (0.47)  $ (0.22)  $ (1.18)  $ (1.04)
Weighted average shares used in loss per share calculation:        
Basic  17,134  12,320  15,346  11,961
Diluted  17,134  12,320  15,346  11,961
(in thousands)
    December 31, December 31,  
    2012 2011  
Cash and cash equivalents    $ 24,212  $ 4,565  
Other currents assets    406  99  
Fixed assets (net)    53  15  
Other assets (net)    2,161  1,385  
Total assets    $ 26,832  $ 6,064  
Accounts payable and accrued expenses     $ 3,798  $ 1,398  
Stockholders' equity    23,034  4,666  
Total liabilities and stockholders' equity    $ 26,832  $ 6,064  
CONTACT: Joseph S. Podolski
         Chief Executive Officer
         (281) 719-3447
         Investor Relations:
         Thomas Hoffmann
         The Trout Group
         (646) 378-2931

company logo

2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,805.82 +27.67 0.16%
S&P 500 2,072.96 +11.73 0.57%
NASDAQ 4,773.0150 +24.6190 0.52%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs